HomeNewsBusinessTwo fintechs fuelled extensive pandemic relief fraud, House report finds

Two fintechs fuelled extensive pandemic relief fraud, House report finds

The 130-page report, product of an 18-month investigation by the House Select Subcommittee on the Coronavirus Crisis, is packed with startling details about how negligible government oversight and a rush to get cash out the door to help devastated businesses created conditions ripe for fraud

December 03, 2022 / 12:44 IST
Story continues below Advertisement
Representative Image
Representative Image

Stacy Cowley

Top executives from two small start-ups that reaped billions of dollars in fees for facilitating Paycheck Protection Program loans turned a blind eye to extensive fraud among their applicants and appear to have themselves collected large relief loans for which they were ineligible, according to a report released by Democratic lawmakers on December 1.

Story continues below Advertisement

The 130-page report, the product of an 18-month investigation by the House Select Subcommittee on the Coronavirus Crisis, is packed with startling details about how negligible government oversight and a rush to get cash out the door to help devastated businesses created conditions ripe for fraud. Some non-bank financial technology companies, known as fintechs, exploited those gaps to collect outsize profits — which they maximized by ignoring typical lending safeguards and, at times, by outright flouting the government aid program’s rules, the report said.

The report is particularly critical of two companies: Womply, a San Francisco marketing software maker, and Blueacorn, a Scottsdale, Arizona, venture created in a hurry specifically to help companies obtain PPP loans. Both set up systems to help lenders process applications from tiny companies at a huge scale, and spent lavishly on marketing. For their work, Womply collected fees exceeding $2 billion and Blueacorn took in $1 billion.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show